A Deep Dive on the Topgolf Callaway Spinoff – The Special Situations Report Episode #46

Episode Summary

Executive Summary: This episode covers major event-driven activity, including Abbott's $23B acquisition of Exact Sciences, TopGolf Callaway's spin-off conversion to a PE asset sale, a buyback at Zymeworks as it pivots to a royalty model, and Biohaven's secondary offering amid pipeline failures. Also discussed: Sinclair's stake in EW Scripps, Warner Bros. Discovery acquisition interest, and activist involvement at Barrick Gold.

Main Topics: Abbott Laboratories Acquires Exact Sciences for $23B (Priority: 5/5): Abbott is acquiring Exact Sciences for $105/share in cash, a 4% spread. Exact Sciences' Cancer Guard test, priced at $689, detects 50+ cancer types. The deal boosts Abbott's diagnostics revenue to over $12B annually. TopGolf Callaway Spin-Off Converted to Asset Sale (Priority: 4/5): TopGolf Callaway is selling a 60% stake in TopGolf and Top Tracer to Leonard Green & Partners for $1.1B, instead of a spin-off. The company will rebrand as Callaway Golf Company (ticker: C). Zymeworks Buyback and Pivot to Royalty Model (Priority: 4/5): Clinical-stage biotech Zymeworks announced a $125M buyback (7% of market cap) and is transitioning to a pharma royalty company, similar to Ligand. Insiders purchased shares in the $11-$14 range; stock now ~$24. Biohaven Secondary Offering and Pipeline Setbacks (Priority: 4/5): Biohaven raised $200M via secondary offering after FDA rejection of its SCA drug and failure of its SMA drug. The company is cutting R&D spend by 60% and focusing on three key platforms, including BHV 7000 for epilepsy. Sinclair Takes 8% Stake in EW Scripps (Priority: 3/5): Sinclair built an 8% stake in EW Scripps, a smaller broadcaster. The deal may face regulatory scrutiny similar to Nexstar-Tegna, which received a DOJ second request. Warner Bros. Discovery Acquisition Interest (Priority: 3/5): Paramount Skydance, Comcast, and Netflix have submitted bids for Warner Bros. Discovery. Paramount Skydance is the only bidder interested in the full company. Stock rose from $18 to $23+. Elliott Investment Management Takes Stake in Barrick Gold (Priority: 2/5): Activist investor Elliott has taken a large stake in Barrick Gold following the CEO's departure. The company plans to refocus on North American assets.

Key Arguments: Abbott's acquisition of Exact Sciences is driven by the potential of the Cancer Guard test to become a standard of care for older adults, offsetting declining COVID-19 testing revenue. TopGolf Callaway's spin-off was converted to an asset sale because the merger proved economically unsuccessful due to market conditions and declining same-store venue sales. Zymeworks' buyback from a clinical-stage biotech is unusual but makes sense as the company pivots to a royalty-based model, focusing on capital allocation and acquisitions. Biohaven's pipeline failures and rapid cash burn make its future highly dependent on the success of BHV 7000 for epilepsy, with results expected in 2025-2026. Sinclair's stake in EW Scripps is a potential tuck-in acquisition, but regulatory hurdles may arise if the Nexstar-Tegna deal closes. Warner Bros. Discovery's potential acquisition is attracting multiple bidders, but Netflix's interest in the library rather than the full company may limit competition. Elliott's involvement at Barrick Gold could drive strategic changes, especially as the company refocuses on North America.

Data Points: Deal Value: $23 billion - Abbott's acquisition of Exact Sciences Acquisition Price: $105 per share - Exact Sciences acquisition by Abbott Spread: 4% (7% annualized) - Exact Sciences deal spread Cancer Guard Test Price: $689 - Exact Sciences' multi-cancer detection test Revenue: $3 billion - Exact Sciences expected 2025 revenue Diagnostics Revenue Post-Deal: $12 billion annually - Abbott's diagnostics revenue after acquisition TopGolf Stake Sale: 60% stake for $1.1 billion - Sale to Leonard Green & Partners Cash Generated: $770 million - Proceeds from TopGolf stake sale Buyback Amount: $125 million (7% of market cap) - Zymeworks buyback announcement Insider Purchase Price: $11-$14 per share - Zymeworks insider purchases Secondary Offering: $200 million - Biohaven's secondary offering R&D Spend Cut: 60% - Biohaven's planned reduction Stock Decline: 80% in the last year - Biohaven stock performance Sinclair Stake: 8% - Stake in EW Scripps Warner Bros. Stock Price: $23+ (up from $18) - Stock increase since acquisition rumors

Pivotal Quotes: "The test is priced at $689 and is recommended annually for adults in the range of 50 to 84 with no known cancer diagnosis over the last three years." — Asif Surya: Discussing Exact Sciences' Cancer Guard test pricing and target demographic. "Seeing a buyback announcement from a clinical stage biotech company with hardly any revenue felt odd, despite the fact that the company had nearly $250 million of net cash on the balance sheet." — Tamana Surya: Commenting on Zymeworks' unusual buyback for a clinical-stage biotech. "The most concerning thing about Biohaven is how quickly the company is burning cash." — Asif Surya: Highlighting Biohaven's financial challenges after pipeline failures.

Implications: Listeners should monitor the Exact Sciences deal for regulatory approval and spread tightening. TopGolf Callaway's asset sale signals a trend of unwinding pandemic-era mergers. Zymeworks' pivot to a royalty model could create value if executed well, while Biohaven's fate hinges on BHV 7000 results. Sinclair's stake in EW Scripps may face DOJ scrutiny, and Warner Bros. Discovery's bidding war could drive further stock gains.